New Dual-Action drug shows promise for kidney cancer patients
NCT ID NCT07488572
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread. The drug works in two ways: it helps the immune system attack cancer cells and blocks blood vessels that feed tumors. About 60 participants will receive the drug every three weeks to see if tumors shrink or stop growing. The goal is to find a better first-line treatment for those who cannot take standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yivoximab (AK112)
What this could lead to
If successful, this could offer a new first-line treatment option for people with advanced kidney cancer who cannot take standard therapies.
What could go wrong
This is an early Phase 2 study with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China